Loading...
•
Sep 30, 2020
CryoPort Q3 2020 Earnings Report
Reported solid performance and positive trends, driven by strength in Biopharma and increased activity in Reproductive Medicine.
Key Takeaways
Cryoport reported solid Q3 2020 results, driven by continued strength in Biopharma and Reproductive Medicine. The company completed milestone acquisitions of MVE Biological Solutions and CRYOPDP, expanding its global presence and capabilities. Cryoport is optimistic for continued growth in 2020 and strong momentum entering 2021, supported by an increasing number of regenerative medicine clinical trials and partnerships.
Regenerative medicine clinical trials supported by Cryoport increased to 517.
Reproductive Medicine benefited from increased activity as fertility clinics resumed operations.
Signed definitive agreements for the acquisitions of MVE Biological Solutions and CRYOPDP.
Cryoport is supporting 26 separate clinical trials related to COVID-19.
Forward Guidance
Cryoport anticipates up to 21 MAA or BLA submissions for Cryoport-supported products in 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...